Praxis Precision Medicines, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PRAX research report →
Range $162 – $1201
Price Chart
About the company
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression.
- CEO
- Marcio Silva De'Souza
- IPO
- 2020
- Employees
- 168
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on PRAX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.40B
- P/E
- -23.80
- Fwd P/E
- 53.46
- PEG
- -79.96
- P/S
- 0.00
- P/B
- 7.07
- EV/EBITDA
- -22.73
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -29.41%
- ROIC
- -32.27%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-140,000+99.9%
- Op Income
- $-326,198,000
- Net Income
- $-303,268,000-65.9%
- EPS
- $-13.48-32.0%
- OCF Growth
- -89.0%
- FCF Growth
- -89.1%
- 52W High
- $392.70
- 52W Low
- $160.11
- 50D MA
- $286.77
- 200D MA
- $314.55
- Beta
- 2.84
- RSI (14)
- 55
- Avg Volume
- 473.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Praxis said both lead late-stage programs remain on track for approvals and launches, while Q2 spending rose as the company built for commercialization.· August 6, 2026
- FDA mid-cycle reviews for ulixacaltamide and relutrigine were described as positive, with no AdCom planned for either program and no findings from the FDA’s BIMO inspections.
- Ulixacaltamide’s ET NDA is still expected to be decided by about January next year, and relutrigine’s PDUFA target is now December 27 after a major amendment extended review.
- Management said commercialization preparations are well underway, including hired and trained teams, distribution setup, inventory build, and a commercial field force for ulixacaltamide.
- Vormatrigine’s POWER1 missed the primary endpoint but hit a key secondary responder endpoint; Praxis plans to amend and restart POWER2 and POWER3 by the fourth quarter.
- Elsunersen received breakthrough therapy designation in June, and EMBRAVE3 is continuing to enroll with top-line results expected next year.
Praxis reported Q2 operating expenses of $96.9 million, including $69.4 million of R&D and $27.5 million of G&A, versus $76 million of operating expenses in Q2 2025. Operating cash usage was $78 million in the quarter versus $55 million a year ago. The company ended Q2 with $1.4 billion in cash, cash equivalents and marketable securities, up from $926 million at December 31, 2025, and said that is enough to fund runway into 2028. For guidance, management said G&A will increase in the second half of the year to support upcoming launches, and reiterated that ulixacaltamide and relutrigine are both in late-stage FDA review with approvals expected in about six months; relutrigine’s new PDUFA target is December 27, and ulixacaltamide is expected by January next year.
Marcio Souza framed the quarter as the moment Praxis shifted from planning to becoming a commercial company, emphasizing that the organization is now building for two near-term launches. He highlighted positive FDA interactions, saying there were no efficacy-related significant issues for ulixacaltamide, no AdCom planned, and no findings from the comprehensive BIMO inspection. His tone was very optimistic and often emphatic, especially on the potential to serve patients with no approved treatments and on the company’s readiness to launch ahead of PDUFA.
Tim Kelly focused on the buildout behind the commercial transition and the quarter’s spending trends. He cited Q2 operating expenses of $96.9 million, operating cash use of $78 million, and cash resources of $1.4 billion at quarter-end versus $926 million at year-end 2025. He said the cash runway remains adequate into 2028 and warned that G&A will rise in the second half as Praxis adds commercial field teams, runs disease-awareness campaigns, builds inventory, and strengthens business systems and infrastructure.
Analysts pressed on FDA review dynamics, launch readiness, payer access, sales force sizing, and whether titration or labeling changes could improve ulixacaltamide persistence. Management said the FDA discussions were broad but straightforward, that titration came up as expected, and that they believe patients who stay on therapy longer are more likely to tolerate and benefit from it; they also described a planned 'hub of the future' to support the first prescription and early titration. On relutrigine, questions centered on whether EMERALD is enriched for sodium-channel-responsive patients and whether broader DEE biology could dilute efficacy; management said the cohort includes patients with pharmacosensitive mechanisms, that severe seizure burden makes placebo response low, and that they expect consistent positive activity across etiologies, though not necessarily identical responses. In commercial questions, Praxis said ulixacaltamide’s neurologist target list is about 13,000 to 15,000, implying a field force of around 300, and reiterated a pricing framework that they believe remains in the $50,000 to $100,000 annual range, though they did not disclose a final price.
The bullish case from the call is that Praxis now has two potentially near-term approvals with visible launch readiness, while FDA feedback appears supportive and there were no inspection issues. Management also believes ulixacaltamide addresses a large unmet need in ET and relutrigine could be first-in-class for SCN2A/SCN8A DEE, with additional lifecycle and label-expansion opportunities ahead.
The main risks are regulatory timing and execution: relutrigine’s review was already extended by a major amendment, vormatrigine’s program missed its primary endpoint and needs redesign, and Praxis is still waiting for final FDA decisions on labels and approvals. Commercially, ulixacaltamide may face payer controls such as step edits through propranolol, and management acknowledged tolerability/discontinuation issues that they hope titration and support programs can mitigate.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 86.3%
- Shares Outstanding
- 27.95M
- Float Shares
- 24.11M
of shares held by institutions
332 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for PRAX, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Janus Henderson Group Ltd. | 3.45M | ▲ 3.45M |
| Jupiter Topco LLC | 3.42M | ▲ 3.42M |
| Fmr LLC | 2.64M | ▲ 320.95K |
| Blackrock, Inc. | 2.23M | ▼ 59.77K |
| Perceptive Advisors LLC | 2.02M | ▼ 11.21K |
| Baker Bros. Advisors LP | 1.75M | 0 |
| Vanguard Group Inc | 1.46M | ▲ 193.65K |
| Orbis Allan Gray Ltd | 1.36M | ▼ 169.74K |
| Vanguard Portfolio Management LLC | 1.30M | ▼ 30.50K |
| Vanguard Capital Management LLC | 1.23M | ▼ 6.27K |
| State Street Corp | 1.04M | ▲ 17.98K |
| Adage Capital Partners Gp, L.L.C. | 981.52K | ▼ 33.96K |
Held by 452 ETFs
Biggest fund positions in PRAX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Sniecinski Megan | other | 21 |
| Nov 13, 26 | Nemiroff Alex | other | 49 |
| Nov 13, 26 | Kelly Timothy Edwin | other | 3 |
| Nov 13, 26 | Mastrocola Lauren | other | 72 |
| Jul 8, 26 | Souza Marcio | other | 20,521 |
| Jul 8, 26 | Souza Marcio | other | 2,600 |
| Jun 24, 26 | DeSimone Jill | other | 3,034 |
| Jun 24, 26 | DeSimone Jill | sell | 10 |
| Jun 24, 26 | DeSimone Jill | sell | 120 |
| Jun 24, 26 | DeSimone Jill | sell | 320 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PRAX coverage
Recent articles, reports, and earnings notes.
No research on PRAX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PRAX report →Praxis Precision: Steady Hands For A Shaky PDUFA Season (Initiating With A Speculative Buy)
seekingalpha.com · Nov 19
Praxis Precision Medicines, Inc. (PRAX) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 16
Praxis Precision Medicines: No Material Changes After Q3 And Investor Day (Rating Kept)
seekingalpha.com · Nov 16
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
globenewswire.com · Nov 12
Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
seekingalpha.com · Nov 11
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 9
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 4
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
globenewswire.com · Oct 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.